Cost-effectiveness of magnetic resonance imaging for diagnosing recurrent ipsilateral deep vein thrombosis
Van Dam, Lisette F.; Van Den Hout, Wilbert B.; Gautam, Gargi; Dronkers, Charlotte E.A.; Ghanima, Waleed; Gleditsch, Jostein; Heijne, Anders Von; Hofstee, Herman M.A.; Hovens, Marcel M.C.; Huisman, Menno V.; Kolman, Stan; Mairuhu, Albert T.A.; Nijkeuter, Mathilde; Ree, Marcel A.Van De; Rooden, Cornelis J.Van; Westerbeek, Robin E.; Westerink, Jan; Westerlund, Eli; Kroft, Lucia J.M.; Klok, Frederikus A.
(2021) Blood Advances, volume 5, issue 5, pp. 1369 - 1378
(Article)
Abstract
The diagnostic workup of recurrent ipsilateral deep vein thrombosis (DVT) using compression ultrasonography (CUS) can be complicated by persistent intravascular abnormalities after a previous DVT. We showed that magnetic resonance direct thrombus imaging (MRDTI) can exclude recurrent ipsilateral DVT. However, it is unknown whether the application of MRDTI in daily
... read more
clinical practice is cost effective. The aim of this study was to evaluate the cost effectiveness of MRDTI-based diagnosis for suspected recurrent ipsilateral DVT during first year of treatment and follow-up in the Dutch health care setting. Patientlevel data of the Theia study (NCT02262052) were analyzed in 10 diagnostic scenarios, including a clinical decision rule and D-dimer test and imaging with CUS and/or MRDTI. The total costs of diagnostic tests and treatment during 1-year follow-up, including costs of falsepositive and false-negative diagnoses, were compared and related to the associated mortality. The 1-year health care costs with MRDTI (range, 1219-1296) were generally lower than strategies without MRDTI (range, 1278-1529). This was because of superior specificity, despite higher initial diagnostic costs. Diagnostic strategies including CUS alone and CUS followed by MRDTI in case of an inconclusive CUS were potential optimal cost-effective strategies, with estimated average costs of 1529 and 1263 per patient and predicted mortality of 1 per 737 patients and 1 per 609 patients, respectively. Our model shows that diagnostic strategies with MRDTI for suspected recurrent ipsilateral DVT have generally lower 1-year health care costs than strategies without MRDTI. Therefore, compared with CUS alone, applying MRDTI did not increase health care costs.
show less
Download/Full Text
Keywords: Cost-Benefit Analysis, Humans, Magnetic Resonance Imaging, Thrombosis, Ultrasonography, Venous Thrombosis/diagnostic imaging, Hematology, Clinical Study, Research Support, Non-U.S. Gov't, Journal Article
ISSN: 2473-9529
Publisher: The American Society of Hematology
Note: Funding Information: The Theia study was supported by an unrestricted grant from BMS/ Pfizer (CV185-390). F.A.K. and C.E.A.D. are supported by the Dutch Thrombosis Association (2013-01). International Network of Venous Thromboembolism Clinical Research Networks (INVENT) endorsed and supported the Theia study. Publisher Copyright: © 2021 by The American Society of Hematology.
(Peer reviewed)